Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD) announced the presentation of data on its lead product, REL-1017, at the 2021 Society of Biological Psychiatry Annual Meeting, occurring virtually from April 29 to May 1, 2021. Six posters will detail REL-1017's effects as an NMDA receptor antagonist, showing promise for treating major depressive disorder (MDD). Previous Phase 2 trials indicated rapid antidepressant effects and good safety profiles. The FDA has granted REL-1017 Fast Track designation for MDD treatment, highlighting its potential in late-stage development.

Positive

• REL-1017 demonstrates rapid onset and sustained antidepressant effects.
• The drug has a favorable safety and tolerability profile confirmed in clinical trials.
• FDA Fast Track designation for REL-1017 indicates its therapeutic potential in major depressive disorder.

Negative

• None.

NEW YORK, April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in six posters at the 2021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually between April 29 and May 1, 2021.

Details of the presentations are below:

Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET
Poster Number: T142
Title: Esmethadone (REL-1017) Antagonizes NMDA Receptors and Reduces Ca2+ Entry in Presence of Quinolinic Acid and Gentamicin 
Session: Poster Session I

Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET
Poster Number: T143
Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors with the GluN2D Subunit
Session: Poster Session I

Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET
Poster Number: F136
Title: Esmethadone (REL-1017) Compares with NMDA Receptor Antagonists in FLIPR Ca2+ Assay 
Session: Poster Session II

Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET
Poster Number: F137
Title: Esmethadone (REL-1017) Shows Similar Effects to Ketamine in Manual Patch Clamp Studies
Session: Poster Session II

Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET
Poster Number: S138
Title: Esmethadone (REL-1017) Restores NMDA Receptor 1 Subunit Expression in an In Vitro Model of Glutamatergic Excitotoxicity 
Session: Poster Session III

Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET
Poster Number: S143
Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors in a Concentration Dependent Manner
Session: Poster Session III

About REL-1017

REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults.  Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.  In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.  The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com

Media Inquiries:
FischTank PR
Relmada@FischTankPR.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting-301280188.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What presentations will Relmada Therapeutics conduct at the 2021 Society of Biological Psychiatry Annual Meeting?

Relmada Therapeutics will present six posters on REL-1017, focusing on its NMDA receptor antagonism and impact on depression.

What is the potential of REL-1017 for treating major depressive disorder?

REL-1017 is entering late-stage studies as an adjunctive treatment for major depressive disorder, showing promising results in Phase 2 trials.

When is the Society of Biological Psychiatry Annual Meeting taking place?

The meeting is being held virtually from April 29 to May 1, 2021.

What is the significance of the Fast Track designation for REL-1017?

The FDA's Fast Track designation for REL-1017 highlights its potential as a rapid-acting treatment for major depressive disorder.

How does REL-1017 compare to ketamine?

In manual patch clamp studies, REL-1017 showed similar effects to ketamine, indicating its effectiveness as an antidepressant.